GMP-Creative Biolabs provides one-stop customer-oriented services including biopharmaceutical contract R&D, process development, cGMP manufacturing, QA & QC solutions for scientific research, preclinical, clinical and commercial supply. We proceed your projects according to your specific demands in quality, timeline and budget, supporting researchers across different therapeutic areas. Clear, open and regular communication with customers is as important to our success as our in-depth scientific knowledge. more
Taking advantage of years of experience in recombinant antibody manufacturing, professional Ph.D level specialist teams as well as advanced cell line construction platforms, Creative Biolabs has come to the unique position to not only have the ability to offer the most comprehensive human cell line services, but also the capability to perform those services in the highest quality and in a most cost and time efficient manner.
Nowadays, therapeutic proteins play an increasingly important role in the pharmaceutical industry, and various recombinant protein therapeutics, such as hormones, growth factors, cytokines and monoclonal antibodies, have been used to treat a variety of diseases, like cancers and diabetes. Recently, human cell lines have emerged as new and powerful alternative approaches for the production of human therapeutic proteins and it is reported that the production of therapeutic proteins in human cell lines is still expanding, with several products currently approved for clinical use and others in clinical development in different therapeutic areas. It is well known that the vast majority of therapeutic proteins require a range of post-translational modifications (PTMs), especially glycosylation, which is a very critical modification of therapeutic proteins. In detail, the glycosylation pattern is of profound importance for the maintaining of the structure, stability, activity, and function of the protein and it also significantly affects the yield, half-life, pharmacokinetics and immunogenicity of the protein. And there are clear differences between the glycosylation profiles produced from hamster, murine and human cells. Although other mammalian cells, such as CHO cell line, can produce similar PTMs to human cells, most also produce a-gal and NGNA, PTMs, that are not present in the structure of human proteins, therefore, human cell lines are the best choice to produce human therapeutic glycoproteins because they can express recombinant proteins with post translation modifications more similar to the natural endogenous human proteins and the right patterns of glycosylation. What’s more, other highlighted advantages of human expression systems include achieving equal productivity to other mammalian cell lines and the production of proteins that lack potentially immunogenic and non-human PTMs, which ensures the safety and efficacy of recombinant protein expression in human cells. Moreover, human cell lines are available for large-scale manufacturing in the pharmaceutical industry due to that they can grow easily in a serum-free suspension culture, reproduce rapidly and have efficient protein production.
We have full understanding of the principle in recombinant protein therapeutics manufacture, that it is of great importance to choose appropriate expression system and vector based on the protein structure and characteristics. With access to various human cell line resources, for each project, Creative Biolabs assembles a strong team with experienced cell line construction scientists and well trained technicians to deliver the most suitable human cell line service according to your budget, timeline, and specific requirements.
Creative Biolabs is capable of providing the following stable cell lines for various proteins expression:
To discuss your Human Cell Lines demands or to request a proposal, please contact us by
For R&D use only, not directly for clinical use.